Page 1,079«..1020..1,0781,0791,0801,081..1,0901,100..»

Developing vaccines is a risky business. Biotechnology is fighting the coronavirus anyway – Mash Viral

Posted: March 29, 2020 at 4:47 am

For biotech companies, responding to a sudden public health crisis, such as the coronavirus, can be a risky business. It can take more than a year to develop a vaccine or treatment. By then, the threat could be gone, leaving little or no demand for medicine.

The current coronavirus pandemic looks different.

The race to beat the pathogen continues, with many biotechnologies now anticipating a large market for coronavirus therapy in 2021 or thereafter. But the starting gun did not fire as soon as the virus started spreading late last year.

There have been many companies that feel bitten once, shy twice, said Jose Travejo, CEO of SmartPharm Therapeutics in Kendall Square.

Companies were shy because drug makers were bitten in the past when they rushed to tackle an epidemic, only to see the danger go away and their efforts go to waste. This happened during a previous coronavirus scare, the 2003 SARS epidemic, which ended before any vaccine maker made money.

There was also Ebola. Then many people forget about swine flu H1N1, Travejo said. So, I think very big pharmacists are hesitant to dive completely into coronavirus.

The opinion of the industry has changed in recent weeks. At LabCentral, the shared workspace where Travejo gene therapy is launched, more than a dozen companies have turned their attention to coronavirus, including SmartPharm.

And this is just one lab in Cambridge.

The number of companies pursuing coronavirus drugs is steadily increasing, according to Yasmen Rahimi, co-director of biotechnology research at Roth Capital Partners, an investment banking firm in Newport Beach, California.

I follow COVID-19 daily, she said. Almost every day we get 10 or 12 companies coming.

Rahimi said the most notable may be Modern, another Cambridge biotech. It is the first company to begin testing a potential coronavirus vaccine for people in the United States.

Modern did not respond to an interview request. But in a public document this week, the company said it was probably not commercially available for the vaccine for at least 12-18 months.

Modern does not think that the virus will enter until then. Instead, its increasing production capacity to produce millions of doses per month.

That may not be enough, according to Dr. Lee Wetzler, an infectious disease specialist at Boston Medical Center.

Just like the flu vaccine, youre not just talking about millions of doses, said Wetzler, who is also a professor at Boston University School of Medicine. Tens tens of millions of doses and more.

Then again, Wetzler added, its hard to predict what this unknown virus will look like in a year. The pandemic may be under control, which would be good for the world, but it may not be as good for companies like Moderna and others who invest in medicines to stop it.

There is a cautionary tale in the once hot biotech Vical that received federal money to chase anthrax, SARS and Ebola vaccines. Fear and funding always fade before Vical manages to cross the finish line, said John Carroll, editor of Endpoints News, a biotechnology publication.

What Vical did was just a flame, he said. They couldnt come up with a vaccine, and after multiple setbacks, they just couldnt do it anymore.

The risk of failure is well understood by James Siestra, CEO of Totient, one of the startup companies at LabCentral that have switched to coronavirus. But he claims that working with the coronavirus will not be useless, even if the disease goes ahead before Totient puts the drug on the market.

As a business case for us, this is great evidence of the strength of our platform, he said.

Sietstra said the same method that Totient would use to attack the coronavirus could be used against other diseases including the companys original goal cancer.

Originally posted here:
Developing vaccines is a risky business. Biotechnology is fighting the coronavirus anyway - Mash Viral

Posted in Biotechnology | Comments Off on Developing vaccines is a risky business. Biotechnology is fighting the coronavirus anyway – Mash Viral

Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and…

Posted: March 29, 2020 at 4:47 am

New Jersey, United States:The Nanoparticles in Biotechnology and Pharmaceuticals Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the Nanoparticles in Biotechnology and Pharmaceuticals market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the Nanoparticles in Biotechnology and Pharmaceuticals Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the Nanoparticles in Biotechnology and Pharmaceuticals market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the Nanoparticles in Biotechnology and Pharmaceuticals market.

The main players featured in the Nanoparticles in Biotechnology and Pharmaceuticals market report are:

Leading players of the Nanoparticles in Biotechnology and Pharmaceuticals market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the Nanoparticles in Biotechnology and Pharmaceuticals market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the Nanoparticles in Biotechnology and Pharmaceuticals market. It also provides useful recommendations for new as well as established players of the Nanoparticles in Biotechnology and Pharmaceuticals market.

Nanoparticles in Biotechnology and Pharmaceuticals Market by Regional Segments:

The chapter on regional segmentation describes the regional aspects of the Nanoparticles in Biotechnology and Pharmaceuticals market. This chapter explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market for Nanoparticles in Biotechnology and Pharmaceuticals.

Analysts who have authored the report have segmented the market for Nanoparticles in Biotechnology and Pharmaceuticals by product, application and region. All segments are the subject of extensive research, with a focus on CAGR, market size, growth potential, market share and other important factors. The segment study provided in the report will help players focus on the lucrative areas of the Nanoparticles in Biotechnology and Pharmaceuticals market. The regional analysis will help the actors to strengthen their position in the most important regional markets. It shows unused growth opportunities in regional markets and how they can be used in the forecast period.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=SGN&utm_medium=003

Highlights of TOC:

Overview: In addition to an overview of the Nanoparticles in Biotechnology and Pharmaceuticals market, this section provides an overview of the report to give an idea of the type and content of the study.

Market dynamics: Here the authors of the report discussed in detail the main drivers, restrictions, challenges, trends and opportunities in the market for Nanoparticles in Biotechnology and Pharmaceuticals.

Product Segments: This part of the report shows the growth of the market for various types of products sold by the largest companies.

Application segments: The analysts who have authored the report have thoroughly evaluated the market potential of the key applications and identified the future opportunities they should create in the Nanoparticles in Biotechnology and Pharmaceuticals.

Geographic Segments: Each regional market is carefully examined to understand its current and future growth scenarios.

Company Profiles: The top players in the Nanoparticles in Biotechnology and Pharmaceuticals market are detailed in the report based on their market share, served market, products, applications, regional growth and other factors.

The report also includes specific sections on production and consumption analysis, key results, key suggestions and recommendations, and other issues. Overall, it offers a complete analysis and research study of the Nanoparticles in Biotechnology and Pharmaceuticals market to help players ensure strong growth in the coming years.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=SGN&utm_medium=003

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

Our Trending Reports

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Excerpt from:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and...

Posted in Biotechnology | Comments Off on Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and…

Agricultural Biotechnology Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and Expected Revenue by 2026 -…

Posted: March 29, 2020 at 4:47 am

New Jersey, United States:The Agricultural Biotechnology Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the Agricultural Biotechnology market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the Agricultural Biotechnology Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the Agricultural Biotechnology market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the Agricultural Biotechnology market.

Global Agricultural Biotechnology Market was valued at USD 35.6 Billion in 2018 and is projected to reach USD 74.92 Billion by 2026, growing at a CAGR of 9.70% from 2019 to 2026.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=35624&utm_source=SGN&utm_medium=009

The main players featured in the Agricultural Biotechnology market report are:

Leading players of the Agricultural Biotechnology market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the Agricultural Biotechnology market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the Agricultural Biotechnology market. It also provides useful recommendations for new as well as established players of the Agricultural Biotechnology market.

Agricultural Biotechnology Market by Regional Segments:

The chapter on regional segmentation describes the regional aspects of the Agricultural Biotechnology market. This chapter explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market for Agricultural Biotechnology.

Analysts who have authored the report have segmented the market for Agricultural Biotechnology by product, application and region. All segments are the subject of extensive research, with a focus on CAGR, market size, growth potential, market share and other important factors. The segment study provided in the report will help players focus on the lucrative areas of the Agricultural Biotechnology market. The regional analysis will help the actors to strengthen their position in the most important regional markets. It shows unused growth opportunities in regional markets and how they can be used in the forecast period.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=35624&utm_source=SGN&utm_medium=009

Highlights of TOC:

Overview: In addition to an overview of the Agricultural Biotechnology market, this section provides an overview of the report to give an idea of the type and content of the study.

Market dynamics: Here the authors of the report discussed in detail the main drivers, restrictions, challenges, trends and opportunities in the market for Agricultural Biotechnology.

Product Segments: This part of the report shows the growth of the market for various types of products sold by the largest companies.

Application segments: The analysts who have authored the report have thoroughly evaluated the market potential of the key applications and identified the future opportunities they should create in the Agricultural Biotechnology.

Geographic Segments: Each regional market is carefully examined to understand its current and future growth scenarios.

Company Profiles: The top players in the Agricultural Biotechnology market are detailed in the report based on their market share, served market, products, applications, regional growth and other factors.

The report also includes specific sections on production and consumption analysis, key results, key suggestions and recommendations, and other issues. Overall, it offers a complete analysis and research study of the Agricultural Biotechnology market to help players ensure strong growth in the coming years.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/agricultural-biotechnology-market/?utm_source=SGN&utm_medium=009

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Agricultural Biotechnology Market Size, Agricultural Biotechnology Market Trends, Agricultural Biotechnology Market Forecast, Agricultural Biotechnology Market Growth, Agricultural Biotechnology Market Analysis

Our Trending Reports

Threat Intelligence Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Here is the original post:
Agricultural Biotechnology Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and Expected Revenue by 2026 -...

Posted in Biotechnology | Comments Off on Agricultural Biotechnology Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and Expected Revenue by 2026 -…

Gear up for the change! Vir Biotechnology, Inc. (VIR) has hit the volume of 562686 – The InvestChronicle

Posted: March 29, 2020 at 4:47 am

Lets start up with the current stock price of Vir Biotechnology, Inc. (VIR), which is $30.85 to be very precise. The Stock rose vividly during the last session to $37.4 after opening rate of $37 while the lowest price it went was recorded $30.22 before closing at $32.75.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -58.87% during the 52-week period from high price, and 164.80% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 562686 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 160.44%, having the revenues showcasing 166.91% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.13B, as it employees total of 217 workers.

During the last month, 2 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 20.80, with a change in the price was noted +16.66. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +115.45% for the period of last 100 days, recording 527,790 in trading volumes.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 29.02%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 7.73%. In the last 20 days, the companys Stochastic %K was 19.17% and its Stochastic %D was recorded 29.17%.

Lets take a glance in the erstwhile performances of Vir Biotechnology, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 160.44%. The shares increased approximately by 1.54% in the 7-day charts and went down by -34.84% in the period of the last 30 days. Common stock shares were driven by 166.91% during last recorded quarter.

Read more here:
Gear up for the change! Vir Biotechnology, Inc. (VIR) has hit the volume of 562686 - The InvestChronicle

Posted in Biotechnology | Comments Off on Gear up for the change! Vir Biotechnology, Inc. (VIR) has hit the volume of 562686 – The InvestChronicle

Is Aytu Bioscience Inc (AYTU) a Winner or a Loser in the Biotechnology Industry – InvestorsObserver

Posted: March 29, 2020 at 4:47 am

The 85 rating InvestorsObserver gives to Aytu Bioscience Inc (AYTU) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 99 percent of stocks in the Biotechnology industry, AYTUs 85 overall rating means the stock scores better than 85 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aytu Bioscience Inc (AYTU) stock is down -16.08% while the S&P 500 has risen 3.65% as of 2:13 PM on Wednesday, Mar 25. AYTU has fallen -$0.32 from the previous closing price of $1.99 on volume of 21,555,025 shares. Over the past year the S&P 500 has fallen -10.00% while AYTU has risen 3.73%. AYTU lost -$1.88 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read more here:
Is Aytu Bioscience Inc (AYTU) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

Posted in Biotechnology | Comments Off on Is Aytu Bioscience Inc (AYTU) a Winner or a Loser in the Biotechnology Industry – InvestorsObserver

Global Agriculture Biotechnology Market Expected to Witness the Highest Growth with ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury…

Posted: March 29, 2020 at 4:47 am

Global Agriculture Biotechnology Market 2019, this report is prepared by in-depth analysis of historical data. The report forecasts the market size by the end of 2026 at an impressive CAGR provided by Reports and Reports. The report offers detailed outline of Agriculture Biotechnology Market and vital market trends. The prime agenda of this report is to provide a detailed analysis of the global, regional and country-level market size, market growth, market status, forecast, sales analysis, value chain optimization, trade regulations, recent developments, opportunities analysis, and importance of the global and national market players, competitive environment, expansion, acquisition, partnerships and technological innovations. The prime market segments considered to prepare this report are key players, regional segments, type and application.

Get Free Sample Copy of Agriculture Biotechnology Market: http://www.milliondollarresearch.com/agriculture-biotechnology-market/955/#RequestSample

The Agriculture Biotechnology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The major players covered in Agriculture Biotechnology Market are: ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, Dow AgroSciences, Eurofins, Evogene, Global Bio-chem Technology, Syngenta, KWS Saat, Marina Biotech, Monsanto.

Agriculture Biotechnology Industry 2020 Global Market Research report presents an in-depth analysis of the Agriculture Biotechnology market size, growth, share, segments, manufacturers, and technologies, key trends, market drivers, challenges, standardization, deployment models, opportunities, future roadmap and 2026 forecast. The report additionally presents forecasts for Agriculture Biotechnology market revenue, consumption, production, and growth drivers of the market.

Get Special Discount on this report: http://www.milliondollarresearch.com/agriculture-biotechnology-market/955/#AskForDiscount

Regions and Countries Level Analysis:

The important regions, considered to prepare this report are North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). The region wise data analyses the trend, market size of each regions Agriculture Biotechnology Market.

Table of Content (TOC)

Chapter 1: Product definition, type and application, Global market overview;

Chapter 2: Global Market competition by company;

Chapter 3: Global sales revenue, volume and price by type;

Chapter 4: Global sales revenue, volume and price by application;

Chapter 5: United States export and import;

Chapter 6: Company information, business overview, sales data and product specifications;

Chapter 7: Industry chain and raw materials;

Chapter 8: SWOT and Porters Five Forces;

Chapter 9: Conclusion.

Continue

List of Tables and Figures

Get Detail information of this report: http://www.milliondollarresearch.com/agriculture-biotechnology-market/955/

Conclusively, this report is a one stop reference point for the industrial stakeholders to get Agriculture Biotechnology Market forecast of till 2026. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, growth drivers of by analyzing the historical overall data of the considered market segments.

Read more:
Global Agriculture Biotechnology Market Expected to Witness the Highest Growth with ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury...

Posted in Biotechnology | Comments Off on Global Agriculture Biotechnology Market Expected to Witness the Highest Growth with ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury…

Lost Smell and Taste Hint COVID-19 Can Target the Nervous System – The Scientist

Posted: March 29, 2020 at 4:44 am

Nearly two weeks ago, Alessandro Laurenzi, a biologist working as a consultant in Bologna, Italy, was mowing the grass in his garden when a friend stopped him and said the mower reeked of fuel. I couldnt smell anything at all, he tells The Scientist. That was in the morning. A few hours later, he went to have lunch and realized he couldnt smell the food he was about to eat and when he took a bite, he couldnt taste it either. Within a few days, he developed symptoms of COVID-19 and called his doctor to ask if he could get tested. Because his symptoms were mild, Laurenzi says, his doctor said no.

Laurenzi had heard anecdotally that many COVID-19 patients in Italy suffered from a loss of smell, so he started reading all the scientific papers he could find to see if his anosmia and ageusia would ever abate. One of the papers, a review published March 13, mentioned that SARS-CoV-2, like other coronaviruses such as SARS-CoV and MERS-CoV, could target the central nervous system, possibly infecting neurons in the nasal passage and disrupting the senses of smell and taste.

Some of the purely respiratory symptoms that you might attribute to the disease, the inability to get air into the lungs, might actually be defects in respiration controlled by the nervous system.

Matthew Anderson, Beth Israel Deaconess Medical Center

Reading this, Laurenzi immediately reached out to the corresponding author, Abdul Mannan Baig, a researcher at Aga Khan University in Pakistan, and asked if his symptoms were reversible. The evidence, Mannan told Laurenzi and reiterated to The Scientist, indicates they will abate, possibly because the loss of sense is caused by inflammation in the area as the body fights the virus, so those symptoms could disappear in seven to 14 days. Lets hope so, Laurenzi tells The Scientist.

Documenting such peculiar symptoms is important, Mannan tells The Scientist, because the loss of smell and taste could be an early warning sign of SARS-CoV-2 infection. Based on the literature, British ear, nose, and throat doctors have now called for adults who lost those senses to quarantine themselves in an attempt to tamp down the spread of the disease, The New York Times reports. The symptoms, Mannan adds, also suggest that the virus has the ability to invade the central nervous system, which could cause neurological damage and possibly play a role in patients dying from COVID-19.

This is something to keep a careful eye on, says Matthew Anderson, a neuropathologist at Beth Israel Deaconess Medical Center in Boston. Theres been some intriguing observations in previous studies on viruses, including coronaviruses, to show that they have the capacity to enter the nervous system. Its important that this be considered for SARS-CoV-2 and for people to do the experiments, including autopsies, to look for signs of this damage.

Because COVID-19 has symptoms similar to the flu, much of the attention could get diverted towards the pulmonary aspect of SARS-CoV-2, while neural involvement may remain covert, Mannan says. When a patient begins to exhibit severe neurological symptoms, such as a loss of involuntary breathing, it may be too late to prevent fatalities.

In a review article first published February 27, Yan-Chao Li of Jilin University in China and colleagues argue that if SARS-CoV-2 infects nerve cells, particularly neurons in the medulla oblongata, which is part of the brain stem that serves as the control center for the heart and the lungs, the damage could contribute to acute respiratory failure of patients with COVID-19.

The epidemiological evidence supports the hypothesis that neurons in the medulla can become infected with SARS-CoV-2 and contribute to a patients breathing problems and potential death. Li and colleagues explain that the time it takes for COVID-19 to progress from first symptoms to difficulty breathing is typically five days; patients are then admitted to the hospital roughly two days later, and a day after that put into intensive care. The latency period is enough for the virus to enter and destroy the medullary neurons, they write.

SARS-CoV-2 enters human cells using a receptor called ACE2. Researchers have reported that ACE2 regulates cardiovascular function, and according to a search of protein databases, many human cell types express ACE2, including lung, heart, kidney, intestine, and brain tissue, Mannan says. There are also multiple ways that the virus could invade the central nervous system, he explains. It might circulate through the blood and then attack ACE2 receptors in the endothelia that lines blood capillaries in the brain, breaching the blood-brain barrier and invading neurons through that route. A breached blood-brain barrier could also cause brain swelling, compressing the brain stem and affecting respiration, Mannan says. The cells innervating the lungs could also become infected, making involuntary respiration more difficult.

Evidence from experiments in mice also suggest that the virus might target the nervous system through the olfactory bulb. In a 2008 study, immunologist Stanley Perlman of the University of Iowa and colleagues showed that SARS-CoVthe virus that caused the SARS outbreak that killed more than 770 people in 2003entered the brains of transgenic mice expressing human ACE2 through neurons in the nose. The virus then rapidly spread to connecting nerve cells. The extensive nerve damage was the major cause of death, the team reported, even though low levels of the virus were detected in the animals lungs.

Although this has not been demonstrated, SARS-CoV-2 could potentially enter the nervous system through the olfactory bulb, as SARS-CoV does in mice.

Death of the animal likely results from dysfunction and/or death of infected neurons, especially those located in cardiorespiratory centers in the medulla, the team wrote. A study with the MERS virus in mice expressing ACE2 showed a similar result, Perlman tells The Scientist. The brain certainly can be readily infected in mice, he notes. Whether this occurs in humans to any great extent is really unknown, but not very likely at this point, given how much larger rodents olfactory bulbs are relative to the overall size of their brains compared with humans and the paucity of evidence in humans.

Still, he says, the fact that COVID-19 patients have lost their sense of smell or taste is interesting because, if the virus infects the nose, it would use the exact same neurons as in the mouse studies to enter the brain. If taking this path, SARS-CoV-2 could work its way up to the olfactory mucosa, which consists of epithelium cells, blood vessels, and the axons from olfactory neurons. This area is connected to the olfactory bulb, via small, sieve-like, tiny openings called the cribriform plate that is located at the base of the frontal lobes of the brain, Mannan explains. Because the brains frontal lobes are close to the olfactory bulb where neurons may be infected, the tissue deeper in the brain could be endangered too.

Infection of the brainstem could cause changes that would affect involuntary respiration, which suggests some of the purely respiratory symptoms that you might attribute to the disease, the inability to get air into the lungs, might actually be defects in respiration controlled by the nervous system, Anderson says.

Mannan emphasizes that the neurological data on SARS-CoV-2, though preliminary, could be important for doctors deciding how to treat patients. Asking about neurological symptomsloss of taste or smell, twitching, seizurescould factor into who might go into acute respiratory failure, or at least who might suffer from it soonest, and allow for more efficient triaging of patients, with a close eye kept on those with neurological symptoms. It is important to screen the patients for neurological signs early and late in the course of COVID-19, he says, as this could be life-saving in our fight against COVID-19 pandemic.

Anderson and Perlman add that postmortem examinations of the brains of patients who died from COVID-19 are essential to understanding the role nerve damage might play in the progression of the disease. Few, if any, autopsies of these patients are being done because of fear of contracting the disease, and if the autopsies are being done, its not likely that examiners are looking at the brain, only the lungs. Theyre just not thinking that the brain could be the site of the problem, Anderson says, and so thats the really important aspect of these reviews, getting that idea out there.

Ashley Yeager is an associate editor atThe Scientist. Email her atayeager@the-scientist.com. Follow her on Twitter@AshleyJYeager.

Read more:
Lost Smell and Taste Hint COVID-19 Can Target the Nervous System - The Scientist

Posted in Iowa Stem Cells | Comments Off on Lost Smell and Taste Hint COVID-19 Can Target the Nervous System – The Scientist

What An Herbalist, Midwife & Integrative MD Says About The Coronavirus – mindbodygreen.com

Posted: March 28, 2020 at 6:44 am

In terms of supplements, needless to say, this herbalist is on board. Romm says there's an arsenal of herbs and supplements we can take to support our immune systemsfrom widely recognized players like zinc and vitamin D to ones we might not be familiar with for immunity, like astragalus and lavender oil.

Let's start with those common supplements: "Nutritionally, if you had to pick the top three we can feel confident about in terms of safety, it would bezinc, vitamin D, and vitamin C. They're safe for anyone at any age, safe during pregnancy and breastfeeding," Romm says.

As for the lesser-known herbs, Romm is partial to adaptogens in order to support the immune system (that includes medicinal mushrooms, like reishi and ashwagandha, and holy basil). She also touts echinacea and astragalus as herbs worth trying for immunitywhile there's no data on them for COVID-19 yet, they do have purported benefits for the common cold.

But Romm's favorite herb in her medicine cabinet is none other than lavender oil, as it helps reduce her anxiety (which, as we know, has quite the impact on our immune systems). "One of my favorites right now is lavender oilit's incredibly effective for a good night's sleep, especially when it's disrupted by anxiety," she explains.

With these herbs and supplements, feel free to take them by capsule, tincture, or even add them to soups and smoothies. While they're great to have on hand, Romm emphasizes that they're not totally necessary (hence the term, supplement). "Don't freak out if you can't find them; just do your best," she assures me.

Read the original here:
What An Herbalist, Midwife & Integrative MD Says About The Coronavirus - mindbodygreen.com

Posted in Integrative Medicine | Comments Off on What An Herbalist, Midwife & Integrative MD Says About The Coronavirus – mindbodygreen.com

Everything You Need to Know About Coronavirus: Before, During, After and How to Build Immunity Against Future Viruses – India New England

Posted: March 28, 2020 at 6:44 am

WALTHAM, MACoronavirus that causes COVID-19 disease is the worst pandemic the world has ever seen. If you are confused with the overwhelming information about the virus, you may want to watch this video interview with Dr. Sailaja Reddy, MD, IFMCP, ABoIM, ABOM, CCMS.

In an exclusive video interview with INDIA New England News, Dr. Reddy explains coronavirus, how it is different from other viruses, how we can prevent it from infection, how it infects and how to take care after recovery from COVID-19.

To watch the full interview, please click here or on the image below.

Dr. Reddy educates, supports, treats and transforms peoples lives by getting to the root cause of illness using the best of science and nature. Dr. Reddy is functional and integrative medicine specialist, amd is founder of RootHealthMD in Framingham, Mass, focusing on reversal of chronic diseases and supports the development of vibrant longevity.

Dr. Reddy did her residency at St. Elizabeths Hospital and received advanced training in obesity medicine, Integrative medicine and culinary medicine. She is a certified physician through Institute of Functional Medicine.

Immunity, says Dr. Reddy, is a defense system that has biological structure and process within humans that protects against diseases.

Our body builds immunity through healthy lifestyle. Diet, genetics and environment play a major role, says Dr. Reddy, adding that one should change lifestyle in order to build immunity.

A diet that is nutrient rich, with low sugar, good quality protein and less processed will strengthen your immune system, says Dr. Reddy. The latest science suggests that being fit boosts our immune systems, and that even a single workout can amplify and improve our ability to fight off germs.

PS: This information is for information purposes only. If you have any discomfort, please consult your physician immediately.

Go here to see the original:
Everything You Need to Know About Coronavirus: Before, During, After and How to Build Immunity Against Future Viruses - India New England

Posted in Integrative Medicine | Comments Off on Everything You Need to Know About Coronavirus: Before, During, After and How to Build Immunity Against Future Viruses – India New England

UK Employees Invited to Send Photos of Their Pets for Arts in HealthCare Pet Gallery – UKNow

Posted: March 28, 2020 at 6:44 am

LEXINGTON, Ky. (March 27, 2020) May is National Pet Month, and Arts in HealthCare invites all UK campus and UK HealthCare employees to submit photos of their pets for a photo exhibition.

Participants may submit up to three photos of their pet(s) that capture their pets personality - whether its funny, playful or sweet. Photographers of all skill levels are welcome to participate. Email your submission(s) along with your pets name electronically tosarah.timmons@uky.edu.The deadline to submit is April 21st, 2020.

At least one photo submission from each participant will be chosen anddisplayed in three staff areas (one by the UK Chandler Hospital Pavilion A staff elevators, one in Chandler Pavilion H, and one in Good Samaritan Hospital) in May as part of National Pet Month. National Pet Month follows National Pet Therapy day, which is on April 30th.

In addition to staff photo submissions, the dogs of the Animal Assisted Therapy Program at UK HealthCare will be featured. The Animal Assisted Therapy program is housed within Integrative Medicine and Health and is also part of Volunteer Services.

Animal Assisted Therapy Program

The core values of the UK Healthcare canine counselors are service, education and research.Their missionis to enhance and improve the experience of all patients, families, caregivers, faculty and staff throughout the UK Healthcare enterprise by providing consistent and compassionate animal-assisted therapy interactions. They strive to utilize each contact as an opportunity to provide the unique enriching experience that only animal-assisted therapy can offer.

The overarching definition of pet therapy, also referred to as animal assisted intervention (AAI) and animal assisted therapy (AAT), isany practice that involves animals as a part of a therapeutic process with the goal of positively affecting human health, by utilizing animals as adjuncts to therapy. Animal assisted therapy is a growing field that helps people recover from or cope with mental health disorders, heart disease, cancer, stress and anxiety. While many types of animals may serve in the area of animal assisted therapy, dogs are the most common of these.

Animal assisted therapy consists of a team which is comprised of a handler and their dog. The handler typically owns and trains the dog before going through an evaluation through a certification organization. Organized therapy dog groups provide educational material to volunteers, screen both volunteers and dogs, and provide liability insurance for the dog and handler when volunteering in a therapy setting. Handlers are not allowed to be paid while working with their dogs. There are numerous local, national and international certification organizations, and many are recognized by the American Kennel Club (AKC) as a path towards achieving an AKC Therapy Dog title for your dog. If you want a therapy dog team to visit you or your patients, call Susan Pressly Lephart, Ph.D., (412-897-3934 orsp.lephart@uky.edu), Integrated Medicine and Health (859-323-4325), or UK HealthCareVolunteer Services (859-323-6023).

Read more from the original source:
UK Employees Invited to Send Photos of Their Pets for Arts in HealthCare Pet Gallery - UKNow

Posted in Integrative Medicine | Comments Off on UK Employees Invited to Send Photos of Their Pets for Arts in HealthCare Pet Gallery – UKNow

Page 1,079«..1020..1,0781,0791,0801,081..1,0901,100..»